Treco to succeed Bolte as CEO of Inozyme
Plus: Seagen’s Siegall to be CEO at Morphimmune and updates from Jasper, Vividion and more
Inozyme Pharma Inc. (NASDAQ:INZY) named Chair Douglas Treco to succeed CEO Axel Bolte, effective April 1. Treco was co-founder, president and CEO of Ra Pharmaceuticals Inc., which was acquired in 2020 by UCB S.A. (Euronext:UCB). Bolte, who founded Inozyme in 2015, is retiring. The company also hired Matthew Winton, former SVP and U.S. head of the multiple sclerosis franchise of Biogen Inc. (NASDAQ:BIIB), as COO. Inozyme is developing treatments for rare diseases impacting the vasculature, soft tissue and skeleton.
Morphimmune Inc. hired Clay Siegall as president and CEO, months after the former Seagen Inc. (NASDAQ:SGEN) president and CEO resigned amid allegations of domestic violence. Siegall co-founded Seagen in July 1997; the company is now being acquired by Pfizer Inc. (NYSE:PFE). Morphimmune is developing small molecules to treat cancer using its targeted effector platform, which is based on the research of Purdue University’s Philip Low...